EU-307

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameEU-307

Drug Alias NameGPC3 IL18 CART cell therapy (Eutilex)EU307

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionT lymphocytes stimulantsImmunologic cytotoxicityGlypican-3 inhibitors +[4]

TargetsGlypican-3Interleukin 18

Therapy Area/IndicationsLiver NeoplasmsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesEutilex

China Registration ClassN/A

Develop Information

Active CompaniesEutilex

Inactive CompaniesN/A

Active IndicationsLiver NeoplasmsCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A